FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...
The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...
Jefferies analyst Michael Yee assigned a Buy rating to Viridian Therapeutics (VRDN – Research Report) today and set a price target of ...
Tenthoff covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of -12.6% and a 32.18% ...
Barchart on MSN1d
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...
(NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. 'We are honored ...
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024 ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback